GlassScriptPhysician profile
Stephen H Mason
NPI 1134141484
$1,732.46
in general payments reported to CMS, 2019-2025
13 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $117 · 2021: $73.52 · 2022: $141 · 2023: $529 · 2024: $361 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.14 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $435.96 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $375.09 | 2019-2025 | |
| Amgen INC. | $371.40 | 2019-2024 | Otezla |
| Abbvie INC. | $158.40 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $144.75 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $67.09 | 2022-2024 | Blu-U, Odomzo |
| Kerecis Limited | $61.61 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Lilly USA, LLC | $32.03 | 2019-2020 | |
| Genzyme Corporation | $20.20 | 2021 | |
| Incyte Corporation | $19.56 | 2024 | Opzelura |
| Biofrontera INC. | $18.13 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Biowound Solutions, INC. | $16.56 | 2025 | Bio-Connekt |
| Galderma Laboratories, L.P. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.